Primary sclerosing cholangitis - The arteriosclerosis of the bile duct?

Lipids in Health and Disease

Volumn 6, Issue , 2007, Pages

  Fickert, Peter ^a   Moustafa, Tarek ^a   Trauner, Michael ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; REACTIVE OXYGEN METABOLITE; VASCULAR CELL ADHESION MOLECULE 1; GLYCOPROTEIN P; P GLYCOPROTEIN 2; P-GLYCOPROTEIN 2; UNCLASSIFIED DRUG;

ARTERIOSCLEROSIS; ARTICLE; BILE DUCT DISEASE; BILE SECRETION; CELL ACTIVATION; CELL INTERACTION; CYTOKINE RELEASE; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FOAM CELL; HOMEOSTASIS; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LIPID BLOOD LEVEL; MACROPHAGE; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; ANIMAL; CLASSIFICATION; DISEASE MODEL; GENETICS; MOUSE; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SCLEROSING CHOLANGITIS; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIOSCLEROSIS; BILE DUCT DISEASES; CHOLANGITIS, SCLEROSING; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; MICE; MICE, KNOCKOUT; P-GLYCOPROTEINS;

EID: 33846897181     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-6-3     Document Type: Article

References (44)

1. Atherosclerosis. AJ Lusis, Nature 2000 407 6801 233 241 10.1038/35025203 11001066
2. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. CJ Murray AD Lopez, Lancet 1997 349 9063 1436 1442 10.1016/S0140-6736(96)07495-8 9164317
3. A role for oxidized phospholipids in atherosclerosis. JA Berliner AD Watson, N Engl J Med 2005 353 1 9 11 10.1056/NEJMp058118 16000351
4. Inflammation in atherosclerosis. P Libby, Nature 2002 420 6917 868 874 10.1038/nature01323 12490960
5. Primary sclerosing cholangitis. FD Mendes KD Lindor, Clin Liver Dis 2004 8 1 195 211 10.1016/S1089-3261(03)00127-2 15062201
6. The cholangiopathies: disorders of biliary epithelia. KN Lazaridis M Strazzabosco NF Larusso, Gastroenterology 2004 127 5 1565 1577 10.1053/j.gastro.2004.08.006 15521023
7. New mouse models for lipoprotein metabolism and atherosclerosis. MP de Winther MH Hofker, Curr Opin Lipidol 2002 13 2 191 197 10.1097/00041433- 200204000-00011 11891422
8. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. P Fickert A Fuchsbichler M Wagner G Zollner A Kaser H Tilg R Krause F Lammert C Langner K Zatloukal HU Marschall H Denk M Trauner, Gastroenterology 2004 127 1 261 274 10.1053/j.gastro.2004.04.009 15236191
9. Animal models for primary sclerosing cholangitis. JM Vierling, Best Pract Res Clin Gastroenterol 2001 15 4 591 610 10.1053/bega.2001.0207 11492970
10. Mouse models of arteriosclerosis: from arterial injuries to vascular grafts. Q Xu, Am J Pathol 2004 165 1 1 10 15215157
11. Etiopathogenesis of primary sclerosing cholangitis. CA O'Mahony JM Vierling, Semin Liver Dis 2006 26 1 3 21 10.1055/s-2006-933559 16496229
12. The continuing importance of bile acids in liver and intestinal disease. AF Hofmann, Arch Intern Med 1999 159 22 2647 2658 10.1001/archinte.159.22.2647 10597755
13. Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. CM Van Nieuwkerk RP Elferink AK Groen R Ottenhoff GN Tytgat KP Dingemans MA Van Den Bergh Weerman GJ Offerhaus, Gastroenterology 1996 111 1 165 171 10.1053/gast.1996.v111.pm8698195 8698195
14. NUCLEAR RECEPTORS IN LIPID METABOLISM: Targeting the Heart of Dyslipidemia. SW Beaven P Tontonoz, Annu Rev Med 2006 57 313 329 10.1146/annurev.med.57.121304.131428 16409152
15. Bile acids decrease hepatic paraoxonase 1 expression and plasma high-density lipoprotein levels via FXR-mediated signaling of FGFR4. A Gutierrez EP Ratliff AM Andres X Huang WL McKeehan RA Davis, Arterioscler Thromb Vasc Biol 2006 26 2 301 306 10.1161/01.ATV.0000195793.73118.b4 16284190
16. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. EA Hanniman G Lambert TC McCarthy CJ Sinal, J Lipid Res 2005 46 12 2595 2604 10.1194/jlr.M500390-JLR200 16186601
17. LXRs and FXR: The Yin and Yang of Cholesterol and Fat Metabolism. NY Kalaany DJ Mangelsdorf, Annu Rev Physiol 2005
18. Liver X receptor signaling pathways in cardiovascular disease. P Tontonoz DJ Mangelsdorf, Mol Endocrinol 2003 17 6 985 993 10.1210/me.2003-0061 12690094
19. A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids. DM Shih HR Kast-Woelbern J Wong YR Xia PA Edwards AJ Lusis, J Lipid Res 2006 47 2 384 392 10.1194/jlr.M500378-JLR200 16269825
20. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. D Duran-Sandoval B Cariou F Percevault N Hennuyer A Grefhorst TH van Dijk FJ Gonzalez JC Fruchart F Kuipers B Staels, J Biol Chem 2005 280 33 29971 29979 10.1074/jbc.M501931200 15899888
21. Bile acids induce adhesion molecule expression in endothelial cells through activation of reactive oxygen species, NF-kappaB, and p38. P Qin X Tang MM Elloso DC Harnish, Am J Physiol Heart Circ Physiol 2006 291 2 H741 7 10.1152/ajpheart.01182.2005 16582018
22. CAMs and Rho small GTPases: gatekeepers for leukocyte transendothelial migration. Focus on "VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration". BR Alevriadou, Am J Physiol Cell Physiol 2003 285 2 C250 2 12842833
23. Effects of bile acids on biliary epithelial cells: proliferation, cytotoxicity, and cytokine secretion. T Lamireau M Zoltowska E Levy I Yousef J Rosenbaum B Tuchweber A Desmouliere, Life Sci 2003 72 12 1401 1411 10.1016/S0024-3205(02)02408-6 12527037
24. Tumor necrosis factor-alpha and interferon-gamma directly impair epithelial barrier function in cultured mouse cholangiocytes. S Hanada M Harada H Koga T Kawaguchi E Taniguchi R Kumashiro T Ueno Y Ueno M Ishii S Sakisaka M Sata, Liver Int 2003 23 1 3 11 10.1034/j.1600-0676.2003.01707.x 12640721
25. Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis. S Sakisaka T Kawaguchi E Taniguchi S Hanada K Sasatomi H Koga M Harada R Kimura M Sata N Sawada M Mori S Todo T Kurohiji, Hepatology 2001 33 6 1460 1468 10.1053/jhep.2001.25086 11391535
26. The immunobiology of primary sclerosing cholangitis. CA Aoki CL Bowlus ME Gershwin, Autoimmun Rev 2005 4 3 137 143 10.1016/j.autrev.2004.09.003 15823499
27. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. D Bruemmer AR Collins G Noh W Wang M Territo S Arias-Magallona MC Fishbein F Blaschke U Kintscher K Graf RE Law WA Hsueh, J Clin Invest 2003 112 9 1318 1331 14597759 10.1172/JCI200318141
28. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. CA Cuff D Kothapalli I Azonobi S Chun Y Zhang R Belkin C Yeh A Secreto RK Assoian DJ Rader E Pure, J Clin Invest 2001 108 7 1031 1040 11581304 10.1172/JCI200112455
29. Smad expression in human atherosclerotic lesions: evidence for impaired TGF-beta/Smad signaling in smooth muscle cells of fibrofatty lesions. N Kalinina A Agrotis Y Antropova O Ilyinskaya V Smirnov E Tararak A Bobik, Arterioscler Thromb Vasc Biol 2004 24 8 1391 1396 10.1161/01.ATV.0000133605.89421.79 15166010
30. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. LF Brown B Berse L Van de Water A Papadopoulos-Sergiou CA Perruzzi EJ Manseau HF Dvorak DR Senger, Mol Biol Cell 1992 3 10 1169 1180 1421573
31. Expression of CD44 on bile ducts in primary sclerosing cholangitis and primary biliary cirrhosis. SM Cruickshank J Southgate JI Wyatt PJ Selby LK Trejdosiewicz, J Clin Pathol 1999 52 10 730 734 10674028
32. Expression of osteopontin correlates with portal biliary proliferation and fibrosis in biliary atresia. PF Whitington P Malladi H Melin-Aldana R Azzam CL Mack A Sahai, Pediatr Res 2005 57 6 837 844 10.1203/01.PDR.0000161414.99181. 61 15845635
33. The ADAMTS proteases, extracellular matrix, and vascular disease: waking the sleeping giant(s)! TN Wight, Arterioscler Thromb Vasc Biol 2005 25 1 12 14 15626768
34. Role of ADAMTS-1 in atherosclerosis: remodeling of carotid artery, immunohistochemistry, and proteolysis of versican. AC Jonsson-Rylander T Nilsson R Fritsche-Danielson A Hammarstrom M Behrendt JO Andersson K Lindgren AK Andersson P Wallbrandt B Rosengren P Brodin A Thelin A Westin E Hurt-Camejo CH Lee-Sogaard, Arterioscler Thromb Vasc Biol 2005 25 1 180 185 15539621
35. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. M Suzuki M Murata Y Matsubara T Uchida H Ishihara T Shibano S Ashida K Soejima Y Okada Y Ikeda, Biochem Biophys Res Commun 2004 313 1 212 216 10.1016/j.bbrc.2003.11.111 14672719
36. Thrombospondin 1 acts as a strong promoter of transforming growth factor beta effects via two distinct mechanisms in hepatic stellate cells. K Breitkopf I Sawitza JH Westhoff L Wickert S Dooley AM Gressner, Gut 2005 54 5 673 681 10.1136/gut.2004.042911 15831915
37. Localization of ADAMTS13 to the stellate cells of human liver. M Uemura K Tatsumi M Matsumoto M Fujimoto T Matsuyama M Ishikawa TA Iwamoto T Mori A Wanaka H Fukui Y Fujimura, Blood 2005 106 3 922 924 10.1182/blood-2005-01-0152 15855280
38. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. C Pauli-Magnus R Kerb K Fattinger T Lang B Anwald GA Kullak-Ublick U Beuers PJ Meier, Hepatology 2004 39 3 779 791 10.1002/hep.20159 14999697
39. ABCB4 gene mutations and primary sclerosing cholangitis. O Rosmorduc B Hermelin PY Boelle RE Poupon R Poupon O Chazouilleres, Gastroenterology 2004 126 4 1220 2; author reply 1222-3 10.1053/j.gastro.2004.02.042 15057773
40. Defects in hepatobiliary transport. Genetics and therapy of progressive familial intrahepatic cholestasis type 3. JM deVree, University of Amsterdam 1999
41. Biliary tract calculi in primary sclerosing cholangitis. M Kaw WB Silverman M Rabinovitz RR Schade, Am J Gastroenterol 1995 90 1 72 75 7801953
42. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. P Fickert G Zollner A Fuchsbichler C Stumptner AH Weiglein F Lammert HU Marschall O Tsybrovskyy K Zatloukal H Denk M Trauner, Gastroenterology 2002 123 4 1238 1251 10.1053/gast.2002.35948 12360485
43. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. P Fickert M Wagner HU Marschall A Fuchsbichler G Zollner O Tsybrovskyy K Zatloukal J Liu MP Waalkes C Cover H Denk AF Hofmann H Jaeschke M Trauner, Gastroenterology 2006 130 2 465 481 10.1053/j.gastro.2005.10.018 16472600
44. 2000 George Lyman Duff Memorial Lecture: atherosclerosis is a liver disease of the heart. RA Davis TY Hui, Arterioscler Thromb Vasc Biol 2001 21 6 887 898 11397693